黄芪注射液合盏花素注射液对不稳定型心绞痛的治疗作用

目的　观察黄芪注射液合灯盏花素注射液对不稳定型心绞痛 (UAP)的疗效及可能机制。方法　 76例UAP患者随机分成治疗组 4 0例和对照组 36例 ,在常规治疗基础上 ,治疗组用黄芪注射液合灯盏花素注射液静脉滴注 ,对照组口服抵克力得 ,观察治疗 4周后 2组临床症状、心电图疗效及血小板颗粒膜蛋白溶酶体膜糖蛋白 (CD6 3)、血浆C -反应蛋白 (CRP)水平改善的情况。结果　①治疗组心绞痛缓解、心电图改善的显效率、总有效率与对照组比较无显著性差异 (P >0 .0 5 ) ,而伴随症状 2组比较有显著性差异 (P <0 .0 1,P <0 .0 5 ) ;②治疗 4周后 ,治疗组和对照组间血小板CD6 3、血浆CRP测定值分别显著低于治疗前水平 (P <0 .0 1,P <0 .0 5 ) ;而治疗后 2组间上述指标水平比较无显著性差异 (P >0 .0 5 )。结论　黄芪注射液合灯盏花素注射液能较好地缓解UAP患者的临床症状 ,其作用机制可能与改善心肌缺血、抗血小板活化、减轻炎性反应有关

Effect of Astragalus injection combined with Breviscapine injection on the treatment of unstable angina pectoris

Objective To observe the effect Astragalus injection combined with Breviscapine injection on the treatment of unstable angina pectoris (UAP). Method 76 patients with UAP were randomly divided into two groups. On the basis of routine therapy, patients in control group (n=36) were treated by Ticlopidine. Patients in treatment group (n=40) were treated by Astragalus injection combined with Breviscapine injection. After treatment of 4 weeks, symptoms, ECG, CD63 and plasma C-RP were measured. Results Apparent rate and total effective rate in relaxation of angina pectoris and improvement of ECG in treatment group were not obvious more than those in control group (P>0.05). Improvement of accompanying symptoms in treatment group was superior to that in control group (P<0.01 or P<0.05). CD63 and plasma C-RP after treatment were lower than those before treatment in both groups (P<0.01, P<0.05). Conclusion Astragalus injection combined with Breviscapine injection could effectively relax accompanying symptoms of unstable angina pectoris. Its mechanism may be related to improvement of myocardial ischemia, platelet activation and inflammation response.